Evercore Partners Stock News

The year ahead for the IT Networking sector looks sunny, Evercore ISI says, with "numerous tailwinds" blowing broadly across the sector

Evercore (EVR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Evercore (EVR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

CommScope Holding (COMM) is 6% lower today following a downgrade to In Line at Evercore ISI, which sees "limited" upside for 2022 as the company fights some headwinds

We start out with a short list of guidelines that make it easier to identify dividend stocks that are still worth investing in right now.

Life Storage, Inc. (NYSE:LSI)s stock price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $147.63 and last traded at $145.62, with a volume of 560780 shares changing hands. The stock had previously closed at $146.55. LSI has been the subject of several recent research reports. Evercore []

Evercore ISI analyst Duane Pfennigwerth initiated Sun Country Airlines Holdings Inc (NASDAQ: SNCY ) with

Evercore ISI Stick to Their Hold Rating for Cerner

The e-commerce platform has been under pressure for over a month.

Evercore Inc. found using ticker (EVR) have now 8 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 188 and 133 and has a mean target at 169.13. Given that the stocks previous close was at 132.79 this now indicates there is a potential upside of 27.4%. There is a 50 day moving average of 148.66 and the 200 day moving average is 139.9. The market cap for the company is $5,354m. Visit the company website at: https://www.evercore.com [stock_market_widget type="chart" symbol="EVR" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. It operates through two segments, Investment Banking and Investment Management. The Investment Banking segment offers strategic advisory services, such as mergers and acquisitions, strategic shareholder advisory, special committee assignments, and transaction structuring; Capital Markets Advisory, including equity capital markets, restructuring, debt advisory, private placement advisory, market risk management and hedging, private capital advisory, and private funds; and research, sales, and trading professionals services on a content-led platform to its institutional investor clients.

LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the Offering), BELLUS Health Inc. (BELLUS Health or the Company) (TSX and Nasdaq: BLU) today announced that it has entered into an underwriting agreement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, and including LifeSci Capital as lead manager and H.C. Wainwright & C

Pfizer Buys Pharma Rival Arena In All-Cash Deal Worth $6.7 Billion Shares of Arena Pharmaceuticals have doubled in price in premarket trading after Pfizer announced that it had struck a deal to acquire its smaller rival for $100/share in a deal that values the San Deigo-based Arena at $6.7 billion. Pfizer believes it can finance the deal with cash on hand, and thanks to covid, it sure can. Fattened up with its vaccine profits, Pfizer is clearly seizing the opportunity to put some of that money to work by diversifying and paying growth. Investors in both companies should keep in mind that, as part of the deal, warrants will immediately cease to be outstanding and instead will be converted into the right to receive an amount in cash equal to the product of the excess, if any, of the Merger Consideration over the per-share exercise price of such of the options, multiplied by the number of shares then subject to such Company Option. In the press release, Pfizer''s Mike Gladstone said buying Arena would complement Pfizer''s expertise in immunology, specifically allowing it to better serve patients with immuno-inflammatory diseases. "The proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology, a Pfizer innovation engine developing potential therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options," said Pfizer''s Mike Gladstone. "Utilizing Pfizer''s leading research and global development capabilities, we plan to accelerate the clinical development of etrasimod for patients with immuno-inflammatory diseases." Read the press release below: Pfizer and Arena Pharmaceuticals, Inc.(Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.